This Article Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bunn, P. A. Search for Related Content PubMed PubMed Citation Articles by Bunn, P. A., Jr

Can Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Be Overcome by Different Small-Molecule Tyrosine Kinase Inhibitors?

University of Colorado Health Sciences Center; University of Colorado Cancer Center, Denver, CO

The introduction of inhibitors of the epidermal growth factor receptor (EGFR) pathway marked a new chapter in the treatment of lung cancer patients. Before 1990, no systemic therapy was proven to prolong survival in patients with non–small-cell lung cancer (NSCLC), the leading cause of cancer death in the US. Meta-analyses of studies of systemic chemotherapy (primarily platinum-based doublets) conducted in the 1980s and 1990s demonstrated that chemotherapy improved survival in stage II to IV NSCLC.¹

The EGFR has been known to be overexpressed in the majority of NSCLC tumors for many years.² Phase I and II trials of the small-molecule EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib as well as the anti-EGFR monoclonal antibody cetuximab demonstrated that objective responses occurred in 10% to 15% of patients with advanced NSCLC and other solid tumors.^3-6 Dose-limiting toxicities included skin rash, other cutaneous toxicities, diarrhea, and other GI toxicities. Allergic reactions occurred in some patients receiving cetuximab, and rare patients receiving EGFR TKIs were reported to develop interstitial lung disease.

Randomized single-agent studies versus best supportive care in the second- and third-line setting demonstrated that erlotinib (hazard ratio [HR], 0.73; P .001) and gefitinib (HR, 0.89; P = .087) were associated with improved survival, but this was significant only for erlotinib.^7,8 The reasons for the superior HR for erlotinib are unknown, but likely include the higher relative dose and patient selection factors. Retrospective molecular marker studies from these randomized trials indicated that patients whose tumors had high EGFR expression by gene copy number, or by protein expression, were more likely to have survival benefit; that patients with EGFR mutations were more likely to respond; and that patients with K-ras mutations were less likely to respond.^9,10

Trials combining EGFR TKIs with chemotherapy in unselected, previously untreated NSCLC patients yielded uniformly negative results, and single-agent EGFR TKI trials in unselected patients suggested that outcome might be superior with chemotherapy.^11,12 In marked contrast, prospective patient selection trials using molecular biomarkers have shown high response rates, long progression-free survival, and long survival rates.^13,14 The results of randomized trials in biomarker-selected patients are eagerly awaited.

An exciting advancement in our understanding of acquired resistance to EGFR TKIs was the discovery of additional mutations in exon 20 (T790M) of the EGFR in patients with preexisting activating EGFR mutations. These T790M mutations block binding of erlotinib and gefitinib to the receptor.^15,16 New irreversible EGFR TKIs have been shown to bind to the mutated EGFR and have preclinical activity in such tumors.^17,18 Clinical studies are in progress. The mechanisms of acquired mutations in tumors with wild-type receptors are undefined, and T790M resistance mutations appear to be uncommon in these tumors. It is thus unknown whether these irreversible inhibitors will have activity in acquired resistance not associated with T790M.

Anecdotal reports of responses to a different EGFR inhibitor in patients with acquired resistance and presumed wild-type receptors have been reported.^19,20 The article by Cho et al²¹ in this issue of the Journal of Clinical Oncology is the first reported study of erlotinib after gefitinib therapy. In this report, 21 patients who progressed after gefitinib (apparently while receiving gefitinib or within 4 months of discontinuing gefitinib) were treated with standard doses of erlotinib. The objective response rate was 9.5%, and 29% of patients had a response or stable disease. The median duration of disease control was 125 days. The highest rates of disease control and the longest progression-free survival were observed in patients with wild-type EGFR who had stable disease on gefitinib and were likely not to have resistance resulting from T790M mutations. After disease progression during treatment with erlotinib, two patients were treated with cetuximab, and one had an objective response. It is unclear whether the observed responses to erlotinib were a result of its relatively higher dose schedule or whether the drug was active for other reasons. The overall response to cetuximab as a single agent is only 5%. The response after treatment failure with EGFR TKIs is of interest, and studies evaluating cetuximab with and after erlotinib are reasonable. Studies of newer irreversible EGFR tyrosine kinase inhibitors will undoubtedly be conducted both in patients with and without EGFR mutations, and we can expect to see responses in some patients. It will be important to develop biomarkers for the selection of patients most likely to benefit in this situation.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The author indicated no potential conflicts of interest.

REFERENCES

1. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials: Non-Small Cell Lung Cancer Collaborative Group. BMJ 311:899-909, 1995[Abstract/Free Full Text]

2. Arriagada R, Bergman B, Dunant A, et al: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351-360, 2004[Abstract/Free Full Text]

3. Kris MG, Natale RB, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290:2149-2158, 2003[Abstract/Free Full Text]

4. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21:2237-2246, 2003[Abstract/Free Full Text]

5. Perez-Soler R: Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Clin Lung Cancer 6:S20-S23, 2004 (suppl 1)[Medline]

6. Hanna N, Lilenbaum R, Ansari R, et al: Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 24:5253-5258, 2006[Abstract/Free Full Text]

7. Thatcher N, Chang A, Parikh P, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537, 2005[CrossRef][Medline]

8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005[Abstract/Free Full Text]

9. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al: Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24:5034-5042, 2006[Abstract/Free Full Text]

10. Tsao M, Zhu C, Sakurada A, et al: An analysis of the prognostic and predictive importance of k-ras mutation status in the National Cancer Institute of Canada Clinical Trials Group BR.21 study of erlotinib versus placebo in the treatment of non-small cell lung cancer. J Clin Oncol 24:365s, 2006 (suppl; abstr 7005)

11. Herbst RS, Prager D, Hermann R, et al: TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892-5899, 2005[Abstract/Free Full Text]

12. Giaccone G, Herbst RS, Manegold C, et al: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial–INTACT 1. J Clin Oncol 22:777-784, 2004[Abstract/Free Full Text]

13. Paz-Ares L, Sanchez JM, Garcia-Velasco A, et al: A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients with mutations in the tyrosine kinased (TK) domain of the epidermal growth factor receptor (EGFR). J Clin Oncol 24:369s, 2006 (suppl; abstr 7020)

14. Asahina H, Yamazaki K, Kinoshita I, et al: A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 95:998-1004, 2006[CrossRef][Medline]

15. Kobayashi S, Boggon TJ, Dayaram T, et al: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786-792, 2005[Abstract/Free Full Text]

16. Kosaka T, Yatabe Y, Endoh H, et al: Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res 64:8919-8923, 2004[Abstract/Free Full Text]

17. Kobayashi S, Ji H, Yuza Y, et al: An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res 65:7096-7101, 2005[Abstract/Free Full Text]

18. Kwak EL, Sordella R, Bell DW, et al: Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 102:7665-7670, 2005[Abstract/Free Full Text]

19. Garfield DH: Modern treatment of lung cancer: Case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma. J Clin Oncol 23:7738-7740, 2005[Free Full Text]

20. Viswanathan A, Pillot G, Govindan R: Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer 50:417-418, 2005[CrossRef][Medline]

21. Cho BC, Im C-K, Park M, et al: Phase II study of erlotinib in advanced non–small-cell lung cancer after failure of gefitinib. J Clin Oncol 25:2528-2533, 2007[Abstract/Free Full Text]

This Article Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bunn, P. A. Search for Related Content PubMed PubMed Citation Articles by Bunn, P. A., Jr